All stocks Β· COLINZ
CL

Colinz Laboratories ltd.

COLINZ BSE Drug Manufacturers - Specialty & Generic Healthcare

Colinz Laboratories Limited manufactures and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, in…

ISIN INE923C01011
Listed β€”
Quarters tracked 13
Filings 19 docs

About

Colinz Laboratories Limited manufactures and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynaecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin, etc.; antiritrovirals comprising lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anthelmintics, anti-emetics, anti-inflammatory (NSAIDS), sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormones, sunscreens, vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. In addition, the company offers ayurvedic products comprising anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonics, ulcer healing agents, digestive agents, uterine tonics, anti-diabetics, and general tonics, as well as drugs to treat oligospermia and erectile dysfunction. Further, it provides nutraceuticals, including spirulina tabs/caps, spirulina with vitamins and minerals, omega 3 fatty acids caps in softgel, codliver oil with vitamin caps in soft gel, amino acids tabs/caps, l-arginine with proantocyanidin granules, and hair growth formulations, etc., as well as collagen, glucosamine, and chondroitin tabs. Colinz Laboratories Limited was incorporated in 1986 and is based in Mumbai, India.

Key Metrics

as of Sep 2026
Market Cap10 Cr
P/E19.20
Div Yield0.00 %
Book Valueβ‚Ή39.90
52w Highβ‚Ή87.90
52w Lowβ‚Ή36.10
Face Valueβ‚Ή10.00

Quarterly Results

Rs. Crores Β· hover row for definition
Metric Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023
Sales 1.24 1.75 1.43 1.39 1.57 1.45 1.47 1.86 1.75 1.63 1.71 1.79 1.90
Expenses 1.18 1.66 1.33 1.31 1.44 1.35 1.40 1.69 1.59 1.51 1.57 1.67 1.74
Operating Profit 0.06 0.09 0.10 0.08 0.13 0.10 0.07 0.17 0.16 0.12 0.14 0.12 0.16
OPM % 4.84 5.14 6.99 5.76 8.28 6.90 4.76 9.14 9.14 7.36 8.19 6.70 8.42
Other Income 2.89 0.17 0.08 0.16 0.08 0.08 0.08 0.08 0.07 0.11 0.05 0.08 0.04
Depreciation 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Interest 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Profit before tax 2.90 0.21 0.13 0.19 0.16 0.13 0.11 0.21 0.19 0.19 0.15 0.16 0.16
Tax % 17.24 19.05 30.77 26.32 25.00 -23.08 45.45 23.81 26.32 31.58 26.67 25.00 18.75
Net Profit 2.40 0.17 0.08 0.14 0.12 0.15 0.05 0.16 0.14 0.14 0.11 0.12 0.12
EPS in Rs 9.53 0.67 0.32 0.56 0.48 0.60 0.20 0.64 0.56 0.56 0.44 0.48 0.48

Profit & Loss

Annual Β· Rs. Crores
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Sales 6.146.537.037.156.976.167.537.597.838.058.107.88
Expenses 5.726.046.496.526.385.827.227.247.487.647.657.42
Operating Profit 0.420.490.540.630.590.340.310.350.350.410.450.46
OPM % 6.847.507.688.818.465.524.124.614.475.095.565.84
Other Income 0.480.300.280.150.170.190.130.120.100.090.100.10
Interest 0.050.040.040.050.080.090.070.100.080.120.120.12
Depreciation 0.160.130.130.130.200.190.190.220.220.270.280.30
Profit before tax 0.690.620.650.600.480.250.180.150.150.110.150.14
Tax % 24.6420.9726.1523.3329.1716.0027.7826.67-53.33-27.2740.0035.71
Net Profit 0.510.500.490.460.340.210.130.120.230.140.090.10
EPS in Rs 2.021.981.951.830.740.460.280.260.500.310.200.22
Dividend Payout % 0.000.000.000.000.000.000.000.000.000.000.000.00

Balance Sheet

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Equity Capital 2.522.522.522.523.553.553.543.543.543.543.543.54
Reserves 7.526.966.435.624.143.753.293.303.212.982.712.62
Borrowings 0.390.640.570.270.480.990.380.680.420.761.802.53
Other Liabilities 2.351.701.841.821.761.811.601.652.422.401.701.97
Total Liabilities 12.7811.8211.3610.239.9310.108.819.179.599.689.7510.66
Fixed Assets 1.541.701.581.711.862.032.062.212.412.632.883.16
CWIP 0.000.000.000.000.000.000.000.000.000.000.000.00
Investments 1.111.041.020.660.670.610.360.500.530.410.290.29
Other Assets 10.139.088.767.867.407.466.396.466.656.646.587.21
Total Assets 12.7811.8211.3610.239.9310.108.819.179.599.689.7510.66

Cash Flows

Annual Β· Rs. Crores β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Cash from Operating Activity 2.54-1.451.030.400.472.160.580.120.340.060.580.09
Cash from Investing Activity 0.01-0.230.010.01-0.03-0.16-0.04-0.01-0.11-0.010.000.03
Cash from Financing Activity 0.430.240.230.110.090.080.060.020.01-0.03-0.730.45
Net Cash Flow 2.98-1.451.270.520.522.070.600.120.240.02-0.160.57
Free Cash Flow 2.54-1.711.030.400.432.000.540.120.340.040.580.09
CFO/OP % 650.00-253.00224.0089.00105.00659.00210.0043.00106.0022.00136.0026.00

Ratios

Annual Β· Days / % β€” latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
Debtor Days 49.9336.8944.6557.6963.3677.0372.2280.7978.3166.6560.8362.53
Inventory Days 148.55136.22134.31149.17147.59208.33225.13246.80266.31267.25232.18288.96
Days Payable 80.6494.3194.81103.1576.1790.0049.2944.1691.9355.6860.66116.24
Cash Conversion Cycle 117.8478.8184.15103.71134.78195.36248.06283.42252.70278.23232.35235.25
Working Capital Days -60.6473.22-22.8411.239.950.0079.0189.4572.7271.19100.04110.24
ROCE % 7.206.627.708.086.804.393.393.403.183.003.233.20

Shareholding Pattern

% holding β€” latest first
Holder Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023
Promoters 50.60 66.00 66.00 66.00 66.00 66.00 66.00 66.00 66.00 66.00 66.00 66.00
Public 49.39 34.00 34.00 33.99 34.00 33.99 33.99 34.00 34.00 34.00 34.00 34.00
No. of Shareholders 3,174 3,250 3,212 3,272 3,238 3,216 3,202 3,116 2,980 2,929 2,915 2,873

Corporate Actions

No corporate actions recorded.

Announcements

5 filings